Essex Bio-Tech Repurchases 16,000 Shares, Expands Treasury Stock to 2.23 Million

Bulletin Express10-15

Essex Bio-Technology Limited reported the on-market repurchase of 16,000 ordinary shares on 15 October 2026 under its existing buyback mandate approved on 26 May 2026. The shares were acquired on the Hong Kong Stock Exchange at prices ranging from HKD 2.035 to HKD 2.07, with a volume-weighted average cost of HKD 2.0475 per share. Total consideration amounted to HKD 0.03 million.

Following this transaction, the company’s treasury stock increased to 2.23 million shares, while the number of issued shares in circulation (excluding treasury shares) declined marginally to 564.78 million, representing a 0.0028% reduction. The total issued share capital remains unchanged at 567.01 million shares, as the repurchased shares are being held in treasury and have not been cancelled.

Cumulatively, Essex Bio-Tech has bought back 2.23 million shares—0.39% of its issued share base as at the date of the mandate—against its authorisation to repurchase up to 56.70 million shares. In accordance with Hong Kong Stock Exchange rules, the company is restricted from issuing new shares or disposing of treasury shares until 14 November 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment